Novavax is proud to be at the forefront of the fight against this urgent global healthcare crisis. We are working nonstop to make our vaccine
for the global pandemic a reality. As always, our priority is the safety and well-being of our colleagues, their families, and their communities.
We are committed to delivering novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases. We produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.
Never has our path forward been more clear or the need greater.
“We will draw on our experience in developing vaccine candidates for some of the world’s toughest viral threats and use the power of our innovative recombinant nanoparticle vaccine platform, fortified by our Matrix-M™ adjuvant, to address an urgent need—to reduce the human toll of vaccine-preventable diseases.”
Stanley Erck
President and Chief Executive Officer
Novavax
Novavax scientists accelerate the development of new and promising vaccines by building on years of study and experience. Smart, talented, dedicated, and hardworking, they are driven by a passion to find answers and to solve some of our greatest health challenges.
This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.
